-
Product Insights
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drugs In Development, 2023’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Sector Analysis
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Report Overview Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of acquired immune-mediated disorder that affects the myelin components of the peripheral nervous system. Â CIDP can be monophasic, relapsing, or progressive, developing over eight weeks. People with CIDP experience fatigue, muscle weakness, and a loss of feeling symmetrically in their arms and legs that tends to slowly worsen over time. The CIDP marketed and pipeline drugs market research report provides a...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.